Vir Biotechnology opened lower at $12.90, compared with its previous close of $13.13. In the last trading session, the stock traded between $12.02 and $12.96. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Vir Biotechnology is now worth
$ 36.62
Resulting in a loss of
$ 63.38 (63.38%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-1.02 (-7.79%)
Day High
$12.96
Day Low
$12.02
Day Open
$12.90
Prev Close
$13.13
Volume
14,08,921
1W Return
2.93%
1M Return
7.08%
3M Return
35.58%
6M Return
30.32%
1Y Return
112.03%
Market Cap ($ Mn)
2,074
PE Ratio
-
PB Ratio
1.87
PEG Ratio
-
ROE
-46.56%
ROCE
-44.33%
EPS (TTM)
$-0.57
1 Week
2.93%
1 Month
7.08%
3 Months
35.58%
6 Months
30.32%
9 Months
63.17%
Morgan Stanley lifts Vir Biotechnology price target to $28
Morgan Stanley raised Vir Biotechnology's price target to $28. The previous price target was set at $25. Analyst Michelle Gilson maintained the Overweight rating.
2 days agoVir Biotech ECLIPSE 1 meets primary endpoint in hepatitis delta trial
Phase 3 ECLIPSE 1 trial met primary endpoint with 44% response rate for undetectable virus and ALT normalization at Week 48. Secondary endpoint showed 79% of treated participants attained undetectable virus compared to 0% in control group. Vir Biotechnology shares rose 14.66% to $13.13, hitting a new 52-week high. Company plans global regulatory filing in mid-2027, supported by ECLIPSE 2 and 3 data expected in Q1 2027.
3 days agoVir Biotechnology Q3FY26 Results: R&D expense falls 47% YoY to $80 million
R&D expense fell 47% YoY to $80 million due to non-recurrence of prior-year milestone. Cash position stands at $901 million, excluding $90 million received from Gilead collaboration. VIR-5500 granted FDA Fast Track designation for late-line prostate cancer treatment. Gilead deal provides $90 million upfront and up to $1.74 billion in potential milestones.
8 days agoVir Biotechnology signs $1.875B Gilead deal for cancer drugs
Vir Biotechnology signs up to $1.875 billion collaboration with Gilead Sciences. Includes $65 million cash upfront and $25 million equity investment at 30% premium. Potential milestones reach $1.74 billion for development and commercial success. Focuses on three novel T-cell engagers targeting solid tumors using AI-driven platforms.
29 days agoVir Biotech to present Hep Delta trial data at AASLD meeting
Vir Biotechnology presents Phase 2 SOLSTICE trial data at AASLD 2026. Two oral presentations scheduled for November 8, 2026, in Denver. Regimen combines elebsiran (siRNA) and tobevibart (mAb) for chronic hepatitis delta. Data covers HDV RNA response patterns through Week 96 and NK cell remodelling.
1mo agoVir Biotechnology appoints Aziz Sawaf as CFO effective Oct. 5
Aziz Sawaf appointed as EVP and CFO of Vir Biotechnology. Effective date of appointment is October 5, 2026. Sawaf will lead finance, IT, and investor relations functions. He holds MBEE, MBA, and CFA credentials.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Vir Biotechnology is now worth
$ 36.62
Resulting in a loss of
$ 63.38 (63.38%)
Note: Past profits do not guarantee future returns.
